Patents by Inventor Michael J. Morytko

Michael J. Morytko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20230082167
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: January 14, 2022
    Publication date: March 16, 2023
    Inventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. Ericsson, Bryan A. FIAMENGO, Kristine E. FRANK, Michael M. FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20210061813
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 13, 2019
    Publication date: March 4, 2021
    Applicant: AbbVie Inc.
    Inventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. ERICSSON, Bryan A. FIAMENGO, Kristine E. FRANK, Michael M. FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20180291029
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: November 7, 2017
    Publication date: October 11, 2018
    Applicant: AbbVie Inc.
    Inventors: Neil WISHART, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan R. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20160326181
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: May 12, 2016
    Publication date: November 10, 2016
    Applicant: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan R. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20160222020
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: February 8, 2016
    Publication date: August 4, 2016
    Applicant: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • Tricyclic compounds
    Patent number: 9365579
    Abstract: The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 14, 2016
    Assignee: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • Heterocyclic nuclear hormone receptor modulators
    Patent number: 9193744
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: November 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Andrew Burchat, Thomas D. Gordon, Kelly D. Mullen, David C. Ihle, Michael J. Morytko, Kevin P. Cusack, Gloria Y. Lo Schiavo, Lei Wang, Michael Friedman
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20150210708
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: January 30, 2015
    Publication date: July 30, 2015
    Applicant: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20140349970
    Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 9, 2014
    Publication date: November 27, 2014
    Applicant: ABBVIE INC.
    Inventors: Neil Wishart, Maria A. Argiriadi, Eric C. Breinlinger, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Michael Z. Hoemann, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kelly D. Mullen, Gagandeep Somal, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
    Patent number: 8785639
    Abstract: The invention provides a compound of Formula (Ie), pharmaceutically acceptable salts, or stereoisomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: July 22, 2014
    Assignee: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Kristine E. Frank, Dawn M. George, Eric R. Goedken, Michael Friedman, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Jeffrey W. Voss, Lu Wang, Eric C. Breinlinger, Kelly D. Mullen, Gagandeep Somal, Michael Z Hoemann
  • HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS
    Publication number: 20140162985
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: September 6, 2013
    Publication date: June 12, 2014
    Applicant: ABBVIE INC.
    Inventors: Andrew Burchat, Thomas D. Gordon, Kelly D. Mullen, David C. Ihle, Michael J. Morytko, Kevin P. Cusack, Gloria Y. Lo Schiavo, Lei Wang, Michael Friedman
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20130216497
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 22, 2013
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • Nuclear Hormone Receptor Modulators
    Publication number: 20120238549
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: March 15, 2012
    Publication date: September 20, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Kevin P. Cusack, Thomas D. Gordon, David C. Ihle, Martin E. Hayes, Eric C. Breinlinger, Anna M. Ericsson, Bin Li, Lei Wang, Gloria Y. Martinez, Andrew Burchat, Adrian D. Hobson, Kelly D. Mullen, Michael Friedman, Michael J. Morytko
  • Novel Tricyclic Compounds
    Publication number: 20110311474
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2010
    Publication date: December 22, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. ERICSSON, Bryan R. FIAMENGO, Kristine E. FRANK, Michael FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
  • Novel Tricyclic Compounds
    Publication number: 20110190489
    Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2010
    Publication date: August 4, 2011
    Applicant: Abbott Laboratories
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan R. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller, Eric C. Breinlinger, Kelly D. Mullen, Gagandeep Somal
  • Imidazo based heterocycles
    Patent number: 7709468
    Abstract: The present invention is directed to novel imidazopyrazine and imidazopyrimidine compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: May 4, 2010
    Assignee: Abbott Laboratories
    Inventors: David J. Calderwood, Kristine E. Frank, Patrick Betschmann, Gavin C. Hirst, Eric C. Brieinlinger, Michael J. Morytko, Richard W. Dixon
  • Novel Tricyclic Compounds
    Publication number: 20090312338
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 9, 2009
    Publication date: December 17, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller